4
Changes in Ownership
MADRIGAL PHARMACEUTICALS, INC. Filed Acc 0001210238-25-000005
Director sold 10,000 shares at an average $365.20 ($3,652,009)
- Director acquired 10,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| BATE KENNETH Director | 2025-08-15 | Option exercise | +10,000 | $16.46 | $164,600 | 12,627 | D: show line 1 in the form |
| BATE KENNETH Director | 2025-08-15 | Sale | −2,317 | $363.41 | $842,014 | 10,310 | D: show line 2 in the form |
| BATE KENNETH Director | 2025-08-15 | Sale | −2,516 | $364.24 | $916,428 | 7,794 | D: show line 3 in the form |
| BATE KENNETH Director | 2025-08-15 | Sale | −2,567 | $365.33 | $937,793 | 5,227 | D: show line 4 in the form |
| BATE KENNETH Director | 2025-08-15 | Sale | −600 | $366.14 | $219,683 | 4,627 | D: show line 5 in the form |
| BATE KENNETH Director | 2025-08-15 | Sale | −1,104 | $367.63 | $405,865 | 3,523 | D: show line 6 in the form |
| BATE KENNETH Director | 2025-08-15 | Sale | −896 | $368.56 | $330,226 | 2,627 | D: show line 7 in the form |
| Open-market sales · 10,000 sh · avg $365.20 · $3,652,009 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| BATE KENNETH Director | 2025-08-15 | Option exercise · Stock Option (Right to Buy) | −10,000 | 0 | D: show line 8 in the form |
Loading xslF345X05/wk-form4_1755295493.xml…